



Recent progress in the treatment of advanced RET-mutated medullary thyroid cancer: optimizing patient outcomes

Sunday, 8 September, 15:40–16:40 EEST, Plenary Hall, Amphitheatre

Agenda

15:40	Welcome and introduction	Laura Fugazzola
15:45	Recent evidence in the management of RET-mutated MTC	Laura Locati
16:00	Making treatment decisions in the management of RET-mutated MTC: A case-based discussion	Kee Wong
16:15	Expert perspectives in summary	Rossella Elisei
16:20	Panel discussion	Rossella Elisei, Laura Locati and Kee Wong Moderated by Laura Fugazzola
16:40	Close	




Laura Fugazzola
IRCCS Istituto Auxologico Italiano
Milan, Italy



Laura Locati
University of Pavia
Pavia, Italy



Kee Wong
The Royal Marsden Hospital
London, UK



Rossella Elisei
University of Pisa
Pisa, Italy

Objectives

- > To review the data for systemic first-line treatment of patients with advanced RET-mutated MTC.
- > To discuss appropriate timing of molecular testing and treatment initiation of systemic first-line treatment of RET-mutated MTC.
- > To consider appropriate adverse event management for patients with advanced RET-mutated MTC treated with systemic therapy.